Navigation Links
Genoptix Reports Continued Strong Growth for the Second Quarter and First Half of 2009
Date:7/30/2009

CARLSBAD, Calif., July 30 /PRNewswire-FirstCall/ -- Genoptix, Inc. (Nasdaq: GXDX), a specialized laboratory services provider, today reported revenues of $45.3 million for the second quarter of 2009, which includes a $3.7 million benefit from changes in accounting estimates resulting primarily from strong cash collections related to prior periods. Second quarter revenue increased 62.8% over revenues of $27.8 million for the comparable period in 2008, which included a $864 thousand benefit from changes in accounting estimates resulting primarily from cash collections related to prior periods.

"This has been another season of continued growth and record operating performance as we managed more than 14,200 patient cases in the second quarter, an increase of 52.3% from the number of cases managed during the same period in 2008," said Tina S. Nova, Ph.D., President and CEO of Genoptix. "Our unique physician-directed approach to testing and diagnosis is driving increased demand for our services as we continue to expand our customer base. By the end of June, we were servicing approximately 1,250 community physicians across the country."

Gross profit for the second quarter of 2009 was $28.5 million, or 63.0% of revenues, up from $16.6 million, or 59.7% of revenues, for the second quarter of 2008. Operating income for the second quarter of 2009 was $13.4 million, or 29.6% of revenues, compared to operating income of $5.2 million, or 18.6% of revenues, for the same period in 2008.

Net income was $7.9 million for the second quarter of 2009, on a tax rate of 43.1%, compared to net income of $5.6 million for the second quarter of 2008, when taxed at a rate of 5.1%. Diluted earnings per share, or EPS, for the second quarter of 2009 was $0.44 based on 17.8 million weighted average common shares outstanding. This compares to EPS of $0.32 for the second quarter of 2008, which would have been reduced by approximately $0.13 if taxed at the current rate.

As of June 30, 2009, the Company's total cash, cash equivalents and investment securities were $126.7 million. Cash generated from operations was $14.3 million for the second quarter of 2009, with bad debt expense at approximately 3% of total revenues and days sales outstanding of 54 days, consistent with the comparable prior year period.

First Half 2009 Results

Revenues for the first half of 2009 totaled $84.5 million, including a $5.1 million benefit from changes in accounting estimates resulting primarily from strong cash collections related to prior years. This is an increase of 68.6% over revenues of $50.1 million for the comparable period in 2008, which included a $1.3 million benefit from changes in accounting estimates resulting primarily from cash collections related to prior years.

Gross profit for the first half of 2009 was $52.3 million, or 61.9% of revenues, up from $29.7 million, or 59.3% of revenues, for the first half of 2008. Operating income for the first half of 2009 was $23.6 million, or 27.9% of revenues, compared to operating income of $9.3 million, or 18.6% of revenues, for the same period in 2008.

Net income was $13.8 million for the first half of 2009, on a tax rate of 43.6%. This compares to net income of $10.6 million for the first half of 2008, when taxed at a rate of 3.7%. EPS for the first half of 2009 was $0.77 based on 17.9 million weighted average common shares outstanding. This compares to EPS of $0.60 based on 17.5 million weighted average common shares outstanding for the first half of 2008, which would have been reduced by approximately $0.25 if taxed at the current rate.

For the first half of 2009, cash generated from operations was $19.6 million, while purchases of capital equipment for the same period totaled $2.3 million.

"Our performance in the second quarter was the product of exceptional execution, as we balanced the use of organizational resources with our commitment to providing the highest level of service to our customers," said Sam Riccitelli, Genoptix EVP and COO. "We effectively managed our operational and financial growth throughout the quarter while maintaining a constant level of sales representatives and Cartesian hematopathologists. We ended the second quarter with 26 hematopathologists on staff, later adding four more and increasing the current size of the Cartesian Medical Group to 30 physicians, keeping us on track toward our goal of housing approximately 37 physicians by year-end. Additionally, we will add new sales representatives in the coming quarters, bringing us closer to our goal of approximately 85 representatives by the end of 2009."

2009 Performance Outlook

Recognizing the strength of our collection efforts and financial results in the second quarter, Genoptix expects revenues for the full-year 2009 of between $175 and $180 million, an increase from previous estimates of approximately $170 to $175 million. Total year gross margins are expected to be in the high-fiftieth percentile.

Operating margins for 2009 are expected to be in the mid-twentieth percentile, while net income is expected to be approximately $25 million, up from prior estimates of $22 million. Diluted EPS for the full-year 2009 is now expected to be between $1.40 and $1.45 on approximately 18.1 million shares, increasing from a prior range of $1.20 to $1.25. This assumes a tax rate of approximately 44%, down slightly from initial estimations of 45%.

Based on continued infrastructure expansion and implementation of its strategic plan, the Company projects capital expenditures of $8.5 million for the full-year 2009, which includes approximately $4.5 million in maintenance capital. A planned laboratory expansion will begin later this year and is expected to cost approximately $4 million in 2009 and an additional $4 million in the first quarter of 2010.

Conference Call Information

A conference call will take place on Thursday, July 30, 2009, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time), hosted by President and CEO, Tina S. Nova, Ph.D., and other members of senior management. To access the live conference call via phone, dial 866-770-7129 in the U.S. or Canada and 617-213-8067 for international callers. Please specify to the operator that you would like to join the "Genoptix Second Quarter 2009 Earnings Conference Call." The participant code for the call is 62327967. If you are unable to listen to the live webcast, a replay of the call will be available through Thursday, August 6, 2009. Interested parties can access the rebroadcast by dialing 1-888-286-8010 or 1-617-801-6888 internationally and entering the reservation number 95869060.

The conference call will also be webcast live on the "Investors" section of the Genoptix website at www.genoptix.com. Please connect to the Genoptix website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. If you are unable to listen to the live webcast, a replay will be available through Thursday, August 27, 2009.

About Genoptix, Inc.

Genoptix is a specialized laboratory service provider focused on delivering personalized and comprehensive diagnostic services to community-based hematologists and oncologists. Genoptix is headquartered in Carlsbad, California.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release regarding the Company's business that are not historical facts may be considered "forward-looking statements," including statements regarding the value of the Company's services, the Company's ability to provide high quality services and facilitate personalized medicine, the success of the Company's business model, improving case volumes, increasing revenues, customer adoption and growth, the Company's capacity to manage and support future growth and ability to expand its business, hire additional personnel and consistently provide specialized, personalized and comprehensive diagnostic services, the Company's growth prospects and ability to capture additional market share in the U.S., estimated effective tax rates and the Company's financial guidance for 2009. Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause the Company's results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from the results predicted include, without limitation, commercial and governmental reimbursement decisions, compliance and regulatory risks, financial risks, the Company's ability to hire personnel and manage its growth and the competitive landscape within our industry. These and other risks and uncertainties are detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and most recent Quarterly Report on Form 10-Q and subsequent filings with the United States Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

                              (Financial tables follow)



                                  GENOPTIX, INC.
                  CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
                                   (unaudited)
                        (in thousands, except per share data)


                                           Three Months       Six  Months
                                               Ended            Ended
                                              June 30,          June 30,
                                             --------          --------
                                           2009    2008      2009     2008
                                           ----    ----      ----     ----
    Revenues                            $45,298  $27,825   $84,487  $50,123
    Cost of revenues                     16,772   11,206    32,201   20,381
                                         ------   ------    ------   ------
    Gross profit                         28,526   16,619    52,286   29,742
    Operating expenses:
      Sales and marketing                 7,331    5,170    14,321    9,431
      General and administrative          7,491    5,918    13,881   10,306
      Research and development              287      354       527      671
                                            ---      ---       ---      ---
    Total operating expenses             15,109   11,442    28,729   20,408
                                         ------   ------    ------   ------
    Income from operations               13,417    5,177    23,557    9,334
    Interest and other income               433      694       934    1,653
                                            ---      ---       ---    -----
    Income before income taxes           13,850    5,871    24,491   10,987
    Income tax expense                    5,976      300    10,675      409
                                          -----      ---    ------      ---
    Net income                           $7,874   $5,571   $13,816  $10,578
                                         ------   ------   -------  -------
    Net income per share:
      Basic                               $0.47    $0.34     $0.82    $0.65
                                          -----    -----     -----    -----
      Diluted                             $0.44    $0.32     $0.77    $0.60
                                          -----    -----     -----    -----
    Shares used to compute net income
     per share:
      Basic                              16,891   16,337    16,819   16,235
                                         ------   ------    ------   ------
      Diluted                            17,826   17,512    17,850   17,507
                                         ------   ------    ------   ------


                                       GENOPTIX, INC.
                           CONDENSED CONSOLIDATED BALANCE SHEETS
                                      (in thousands)

                                                  June 30,     December 31,
                                                    2009           2008
                                                    ----           ----
                                                (unaudited)
    Assets
    Current assets:
      Cash and cash equivalents                   $20,984        $38,108
      Short-term investment securities            101,685         64,830
      Accounts receivable, net                     21,398         15,604
      Deferred tax asset                            4,735          4,707
      Other current assets                          2,186          2,179
                                                    -----          -----
    Total current assets                          150,988        125,428
    Property and equipment, net                    12,205         12,189
    Long-term investment security                   3,775          3,775
    Long-term deferred tax asset                    2,400          2,510
    Restricted cash                                   270            360
    Other long-term assets                            371            183
                                                      ---            ---
    Total assets                                 $170,009       $144,445
                                                 --------       --------
    Liabilities and Stockholders' Equity
    Current liabilities:
      Accounts payable and accrued expenses        $6,502         $6,580
      Accrued compensation                          5,197          3,006
      Income tax payable                              571              -
      Deferred revenues                             2,009            365
      Deferred rent                                   281            241
                                                      ---            ---
    Total current liabilities                      14,560         10,192
    Long-term deferred rent                         1,808          1,955
    Other long-term liabilities                       315             79
    Stockholders' equity:
      Preferred stock                                   -              -
      Common stock                                     17             17
    Additional paid-in capital                    150,747        143,616
    Accumulated other comprehensive loss             (614)          (774)
    Accumulated earnings (deficit)                  3,176        (10,640)
                                                    -----        -------
    Total stockholders' equity                    153,326        132,219
                                                  -------        -------
    Total liabilities and stockholders' equity   $170,009       $144,445
                                                 --------       --------



                                    GENOPTIX, INC.
                   CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                     (unaudited)
                                    (in thousands)

                                                             Six Months Ended
                                                                 June 30,
                                                                 --------
                                                              2009     2008
                                                              ----     ----
    Operating activities:
      Net income                                           $13,816   $10,578
      Adjustments to reconcile net income to net cash
       provided by operating activities:
        Depreciation and amortization                        1,666       497
        Provision for doubtful accounts                      2,230     1,458
        Stock-based compensation expense                     4,761     3,208
        Excess tax benefits from stock-based
         compensation awards                                (1,585)      (80)
        Amortization of premium (discount) on
         investment securities, net                             78       (15)
        Deferred taxes                                         (29)        -
        Loss (gain) on sale of property and equipment            6       (19)
      Changes in operating assets and liabilities:
        Accounts receivable                                 (8,024)   (5,519)
        Other current and long-term assets                    (159)     (368)
        Accounts payable and accrued expenses                  559     1,557
        Accrued compensation                                 2,191     1,821
        Income taxes                                         2,414      (160)
        Deferred revenues                                    1,644       (27)
        Deferred rent                                            7        14
                                                               ---       ---
    Net cash provided by operating activities               19,575    12,945
                                                            ------    ------
    Investing activities:
      Purchase of property and equipment                    (2,347)   (2,646)
      Proceeds from sales of property and equipment              -        20
      Purchase of investment securities                    (80,620)  (60,781)
      Proceeds from sales and maturities of
       investment securities                                43,958    50,600
      Purchase of intangibles                                 (150)        -
      Release of restricted cash                                90         -
                                                               ---       ---
    Net cash used in investing activities                  (39,069)  (12,807)
                                                           -------   -------
    Financing activities:
      Proceeds from issuance of common stock, net            1,175     1,109
      Excess tax benefits from stock-based
       compensation awards                                   1,585        80
      Repurchase of restricted stock for payment
       of taxes                                               (390)        -
      Costs paid in connection with public offerings             -      (763)
      Proceeds from exercise of warrants                         -        35
                                                               ---       ---
    Net cash provided by financing activities                2,370       461
                                                             -----       ---
    Net (decrease) increase in cash and cash
     equivalents                                           (17,124)      599
    Cash and cash equivalents at beginning of period        38,108    50,624
                                                            ------    ------
    Cash and cash equivalents at end of period             $20,984   $51,223
                                                           -------   -------

    Supplemental information:
    Income taxes paid                                       $8,292      $569
                                                            ------      ----
    Non-cash investing and financing activities:
    Unrealized gain (loss) on investment securities, net      $271     $(191)
                                                              ----     -----
    Change in accrued purchases of property and
     equipment                                               $(560)     $702
                                                             -----      ----



'/>"/>
SOURCE Genoptix, Inc.
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Genoptix, Inc. to Announce Second Quarter 2009 Financial Results
2. Genoptix Announces Participation at the 29th Annual William Blair Growth Stock Conference
3. Genoptix Announces Participation at the Bank of America and Merrill Lynch 2009 Annual Health Care Conference
4. Genoptix Reports Strong Growth for the First Quarter of 2009
5. Genoptix, Inc. to Announce First Quarter 2009 Financial Results
6. Genoptix Announces Participation at the Cowen and Company 29th Annual Health Care Conference
7. Genoptix Announces Participation at Barclays Capital Global Healthcare Conference
8. Genoptix Reports Strong Full-Year Financial Results for 2008 and Raises Guidance for 2009
9. Genoptix Announces Participation at the RBC Capital Markets 2008 Healthcare Conference
10. Genoptix Reports Strong Financial Results for the Third Quarter and Raises Guidance for Full-Year 2008
11. Genoptix Announces the Addition of New Members to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2016)... ... , ... With the FCPX LUT: Summer pack from Pixel Film ... LUT is a Lookup Table that contains a mathematical formula for modifying an image. ... By manipulating each pixel, LUT's can change each color range differently, it gives the ...
(Date:2/6/2016)... ... February 06, 2016 , ... Research has ... helps to reduce the frequency and level of relapse. , At ... Identity and Purpose,” will explore the critical tasks of the recovery phase and ...
(Date:2/5/2016)... Bethpage, NY (PRWEB) , ... February 05, 2016 , ... ... florist-quality long-stem roses in a variety of colors, assortments and packaging. This staple for ... at any King Kullen location. , For Valentine’s Day, not only are long-stem ...
(Date:2/5/2016)... & Salt Lake City, UT (PRWEB) , ... February 05, 2016 ... ... of Activz Whole-Food Nutrition , announced that the much-anticipated feature with author Jahnavi ... New Really Cool Humans Amateur TV Network. , Each week, on his weekly Whole-Food ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... Feb. 5, 2016 Aethlon Medical, Inc. (Nasdaq: ... and CEO, will be presenting at Source Capital Group,s 2016 ... NY at 2:15 p.m. ET on Wednesday, February ... Panel discussion taking place at 3:15 p.m. ET. ... one hour after the conclusion of the live event. The ...
(Date:2/5/2016)... -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ... markets and sells medical devices and wearable sleep ... and international markets, today announced its corporate and ... Company,s resources to develop its mobile health business, ... more on its major businesses. As of this ...
(Date:2/5/2016)...  Henry Schein, Inc. (NASDAQ: HSIC ), the world,s ... office-based dental, animal health and medical practitioners, announced today ... a majority ownership interest in Dental Cremer S.A., a ... Brazil . --> ... the dental distribution business of Cremer S.A. With 2015 ...
Breaking Medicine Technology: